Targeted drug delivery (site specific drug delivery)

Journal of Scientific and Industrial Research

Volumn 63, Issue 3, 2004, Pages 230-247

  Pandey, Archana ^a   Mishra, Satyendra ^b   Tiwari, Alka ^c   Misra, Krishna ^b  

^a University of Allahabad   (India)

^b UNIVERSITY OF ALLAHABAD   (India)

^c MLN MEDICAL COLLEGE   (India)

Author keywords

Aptamers; Genomics; Micro array; Proteomics; Ribozymes and DNA; Targeted validation

Indexed keywords

PHARMACEUTICAL INDUSTRY;

EID: 1842715729     PISSN: 00224456     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (147)

1. th February 1995.
2. Venter J C, Adams M D, Myers E W, Li P W, Mural R J, Sutton G G, Smith H O, Yandell M, Evans C A, Holt R A, Gocayne J D, Amanatides P, Ballew R M & Huson D H et al., The sequence of the human genome, Science, 291 (2001) 1304-1351.
3. Kumar A, Harrison P M, Cheung K-H, Lan N, Echols N, Bertone P, Miller P, Gerstein M B & Snyder M, An integrated approach for finding overlooked genes in yeast, Nature Biotechnol, 20 (2002) 58-63.
4. Ouzounis C A & Karp P D, The past, present and future of genome, wide re- annatation, Genome Biol, Comment (2002) 2001.1 - comment 2110.6
5. David Bentley interviewed by Rebecca Lawrence, Drug Discovery Today, 6(1) (2001) 13.
6. Ross J S & Ginsburg G S, Integrating diagnostics and therapeutics" revolutionizing drug discovery and patient care. Drug Discovery Today, 7(16) (2002) 859-864.
7. Dubey K K, Singh R K & Misra K, A novel bifunctional fluorescent tag for use in molecular biology, Indian J Chem, 34B (1995) 876-78.
8. Singh Y, Watal G & Misra K, Novel fluorophore for labeling of oligonucleotides, Twentyseventh Nucleic Acids Symp Ser, n44 (2000) 184-185.
9. Singh Y, Misra A & Misra K, Synthesis, characterisation and fluorescence study of some novel naphthalimide derivatives, Indian J Chem, 41B (6) (2002) 1238-1345.
10. Dubey K K, P Kumar P, Singh R K & Misra K, Fluorophores for labeling of DNA/RNA fragments, Nucl Acids Symp Ser, 34 (1995) 177-78.
11. Pandey R K, Dubey K K, Misra K & R K Singh, Modified oligonucleotides as fluorescent probes, Nucl Acids Symp Ser, 35 (1996) 199-200.
12. Pandey R K, Tripathi S & Misra K, Synthesis and hybridisation studies of oligonucleotide sequences with modified fluorescent nucleoside analogs, Nucleoside Nucleotide, 17 (1998) 9 - 11.
13. Tripathi S, Mishra R, Misra K & Yogesh S Sanghvi, An efficient and cost-effective strategy for selective N-acylation of purine and pyrimidine bases of deoxy and ribo nucleosides, Nucl Acids Res, (2003) (Communicated).
14. Tripathi S, Misra K & Yogesh S Sanghvi, Process for selective N- acylation of purine nucleosides, U S Pat No. 6, 541, 626 B2, Aril 01, 2003.
15. Lockhart D J & Winzerler E A, Genomics, gene expression and DNA- arrays, Nature, 405 (2000) 827-836.
16. Miles M F, Micro arrays: lost in a storm of data?, Nat Rev Neurosci, 2 (2001) 441-443.
17. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett L M, Haugen-Strano A, Swensen J, Miki Y et al, BRCA1 mutations in primary breast and ovarian carcinomas, Science, 266 (1994) 120-122.
18. Wooster R, Neuhausen S L, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D et al., Localization of a breast cancer susceptibility gene, BRCA2 to chromosome Bq 12-13, Science, 265 (1994) 2088-2090.
19. Hugot J P, Chamaillard M, Zouali H, Lesage S, Cézard J-P, Belaiche J, Almer S, Tysk S, O'Morain C A, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Pug P, Gowe-Rousseac C, Macry J, Colombel J-F, Sahbatou M & Thomas G, Association of NoD2 leucine-rich repeat variants with susceptibility to Crohn's disease, Nature, 411 (2001) 599-603.
20. Parijs L V, Genetic analysis of immunological disease in the mouse by RNAi, Drug Discovery Ser; IBC's Second Annu Model Organism Drug Discovery, (Hynes Convention Center, Boston M A) (12 August 2003).
21. Paigen K & Eppig J T, A mouse phenome project, Mann Genome, 11 (2000) 715-717.
22. Nehls M C, Deductive Genomes: Industrializing discovery biology and target validation using the mouse models, Drug Discovery Ser; IBC's Second Annu Model Organism Drug Discovey (Hynes Convention Center, Boston M A) (13 August 2003).
23. Glynn R, Development & characterisation of mouse models for complex diseases, Drug Discovery Ser; IBC's Second Annu Model Organism Drug Discovery, (Hynes Convention Center, Boston M A) (13 August 2003).
24. Jazwinska E C, Exploiting human genetic variation in drug discovery and development, A TRENDS guide to genetic variation and genomic medicine, 2002, p. S 30.
25. Palfreyman M G, Human tissue in target identification and drug discovery, Drug Discovery Today, 7(7) (2002) 407.
26. Tornell J & Snaith M, Transgenic system in drug discovery from target identification to humanized mice, Drug Discovery Today, 7(8) (2002) 461.
27. Dean P M, Zanders E D & Bailey D S, Industrial scale genomics based drug design and discovery. A TRENDS Guide to genetic variation and genomic medicine marct, 2002, p. S 37.
28. Jacnisch R, Germ line integration and mendelian transmission of the exogenous Moloney leukemia virus, Proc Natl Acad Sci USA, 73 (1976) 1260-1264.
29. Gordon J W & Ruddle F H, Genetic transformation of mouse embryos by microinjection of purified DNA, Science, 214 (1981) 1244-1246.
30. Palmiter R D, Brinster R L, Hammer R E, Trumbauer M E, Rosenfeld M G, Birnberg N C & Evans R M, Dramatic growth of mice that develop from eggs microinjected with metallothionein growth hormone fusion genes. Nature, 300 (1982) 611-615.
31. Kreig A M, Yi A-K, Matson S, Waldschmidt T J, Bishop G A, Teasdale R, Koretsky G A & Klinman D M, CpG motif bacterial DNA trigger direct β - cell activation, Nature, 374 (1995) 546-549.
32. Zamecnik P C & Stephenson M L, Inhibition of Rous sarcoma virus replication and cell transformation by specific oligodeoxynucleotide, Proc Natl Acad Sci USA, 75 (1978) 80-284.
33. Dean N M, Functional genomics and target validation approach using antisense oligonucleotide technology, Curr Opin Biotechnol, 12 (2001) 622-625.
34. Thompson J D, Application of antisense and si RNAs during preclinical drug development, Drug Discovery Today, 7(17) (2002) 912-917.
35. Hogrefe R I, An antisense oligonucleotide primer, Antisense Nucl Acid Drug Dev, 9 (1999) 351-357
36. Baker B F, Condon T P, Koller E, Mackay R A, Siwkouski A M, Vickers T A & Monia B P, Discovery and analysis of antisense oligonucleotide activity in cell culture, Methods, 23 (2001) 191-198.
37. Neilsen P E et al., Sequencing - selective recognition of DNA by stand displacement with a thymine- substituted polyamide, Cancer Res, 15 (1991) 5468-5473.
38. Inversen P L, Phosphorodiamidate morpholino oligomers: Favorable properties for sequence- specific gene inactivation, Curr Opin Mol Ther, 3 (2001) 235-238.
39. Orum H & Wengel J, Locked Nucleic acids: a promising molecular family for gene function analysis and antisense drug development, Curr Opin Mol Ther, 3 (2001) 239-243.
40. Akhtar S & Agrawal S, In vivo studies with antisense oligonucleotide, Trends Pharmacol Sci, 18 (1997) 12-18.
41. Crooke S (Ed.), Antisense research and application (Springer, New York) 1998.
42. Wickstrom E, Clinical trails of genetic therapy with antisense DNA & DNA vectors (Marcel Dekker, New York) 1998.
43. Pandey A, Mishra S & Misra K, Immunostimulation, the sense in antisense technology, Indian J Biotechnol, 2 (2) (2003) 175-183.
44. Bhagat L, Zhu F- G, Yu D, Tang J, Wang H, Kandimallla E R, Zhang R & Agrawal S, CpG penta & hexadeoxyribonucleotides as potent immunomodulatory agents, Biomed Biophys Res Commun, 300 (2003) 853-861.
45. Yu D, Kandimalla E R, Zhao Q, Bhagat L, Cong Y & Agrawal S, Requirement of nucleobase proximal to CpG dinucleotide for immunoistimulatory activity of synthetic CpG DNA, Bioorg Med Chem, 11 (2003) 459-464.
46. Uhlmann E, Mechanism & applications of immunoistimulatory CpG oligos, Nucleic acids in drug discovery, innovations in tools and targets (Mandalay Bay Resort and Casino, Las Vegas N V) April 30- May 2 2003.
47. Tiwari A and Misra K, Antisense approach for chemotherapy of some viral diseases (Review), Ann Neurosci, 3 (1992) 1-11.
48. Casey B P & Glazer P M, Gene Targeting Via triple helix formation, Prog Nucl Acid Res Mol Biol, 67 (2001) 163-192.
49. Fire A, Xu S Q, Montgomery M K, Kostas S A, Driver S E, Mello C C, Potent and specific genetic interference by double stranded RNA in Caenorhabditis elegans, Nature, 391 (1998) 806-811.
50. Guo S & Kemphues K J, Par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/ Thr Kinase is asymmetrically distributed, Cell, 81 (1995) 611-620.
51. Shuey D J, McCallus, D E & Giordano T, RNAi: gene silencing in therapeutic intervention, Drug Discovery Today, 7(20) (2002) 1040-1046.
52. Hutvagner G & Zamore P D, Nature abhors a double strand, Curr Opin Genet Dev, 12 (2002,) 225-232.
53. Elbashir S M, Lendeckel W & Tuschl T, NA interference is mediated by 21 and 22- nucleotide RNAs, Genes Dev, 15 (2001) 188-200.
54. Ahlquist P, RNA depended RNA polmerases, viruses, and RNA Silencing, Science, 296 (2002) 1270-1273.
55. Zamore P D, Tuschl T, Sharp P A & Bartel D P, RNAi: double stranded RNA directs the ATP- dependent cleavage of mRNA at 21-to 23 nucleotide interval, Cell, 101 (2000) 25-33.
56. Yu J Y, DeRuiter S L, & Turner D L, RNA interference by expression of short interfering RNAs and hairpin RNAs in mammalian Cells, Proc Natl Acad Sci USA, 99 (2002) 6047-6052.
57. Lipardi C, Wei O, & Paterson B M, RNAi as random degradative PCR; siRNA primers convert mRNA into dsRNAs that are degraded to generate new si RNAs, Cell, 107 (2001) 297-307.
58. Dobrosotskaya I Y, Seegmiller A C, Brown M S, Goldstein J L & Rawson R B, Regulation of SREBP Processing and membrane lipid production by phospholipids in Drosophila, Science, 296 (2002) 879-883.
59. Kamath R S, Fraser A G, Dong, Y, Poulin G, Durbin R, Gotta M, Kanapin A, Bot N L, Moreno S, Sohrmonn M, Welchman D P, Zipperlen P & Ahringer J, Systematic functional analysis of the Caenorhabditis elegans genome using RNAi, Nature, 421 (2003) 231-237.
60. Elabashir S M, Harborth J, Weber K & Tuschl T, Analysis of gene function in somatic mammalian cells using small interfering RNAs, Methods, 26 (2002) 199-213.
61. Paul C P, Good P D, Winer I & Engelke D R, Effective Expression of small interfering RNA in human cells Nature Biotechnol, 20 (2002) 505-508.
62. Donze O & Picard D, RNA interference in mammalian cells using siRNA synthesized with T7 RNA polymerase. Nucl Acids Res, 30 (2002) c 46.
63. Paddison P J, Caudy A A & Hannon G J, Stable suppression of gene expression by RNAi in mammalian cells, Proc Natl Acad Sci USA, 99 (2002) 1443-1448.
64. Brummelkamp T R, Bernards R, & Agami R, A system for stable expression of short interfering RNAs in mammalian cells, Science, 296 (2002) 550-553.
65. Lee N S, Dohjima T, Bauer G, Li H, Li M-J, Ehsani A, Salvaterra P & Rossi J, Expression of small interfering RNAs targeted against HIV- I rev. Transcripts in human cells. Nat Biotechnol, 19 (2002) 500-505.
66. Sijen T, Fleenor J, Simmer F, Thijssen K L, Parrish S, Timmons L, Plasterk R H A, & Fire A, On tire role of RNA amplification in ds RNA- triggered gene Silencing, Cell, 107 (2001) 465-476.
67. Vargeese C, Ahringer J & Ruvkum G, Genome- wide RNAi analysis of (elegans fat regulatory genes) TIDES-oligonucleotide and peptide technology conference (Mandalay Bay Resort and Casino Las Vegas, NV, USA) (April 28-May 1, 2003).
68. Samarsky D, RNAi in drug development. Nucleic acids in drug discovery innovation in tools and targets, (Mandalay Bay Resort and Casino, Las Vegas, NV) April 28- May 1 2003.
69. Cech R, Zaug A J & Grabowski P J, In vitro splicing of the ribosomal RNA precursor of Tetrahymena; Involvement of a guanosine nucleotide in the excision of the intervening sequence, Cell, 29 1981) 487.
70. Guerrier- Takada C, Gardiner K, Marsh T, Pace N & Altman S, The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme, Cell, 35 (1983) 849-857.
71. Singh Y, Misra A, Tripathi S & Misra K, Ribozymes- a new approach for modeling gene expression. J Sci Ind Res, 61 (2002) 775-785.
72. Sullenger B A & Gilboa E, Emerging clinical applications of RNA, Nature, 418 (2002) 252-258.
73. Usman N & Blatt L M, Nuclease resistant synthetic ribozymes; developing a new class of therapeutics, J Clin Invest, 106 (2000) 1197-1202.
74. Amado R G, Mitsuyasu R T, Symonds G, Rosenblatt J D, Zack J, Sun L-Q & Miller M A phase 1 trail of autologous CD34+ hematopoietic progenitor cells transduced with an anti- HIV ribozyme, Hum Gen Ther, 10 (1999) 2255-2270.
75. Usman N and Blatt L M, Nuclease resistant synthetic ribozymes; developing a new class of therapeutics, J Clin Invest, 106 (2000) 1197-1202.
76. Pavco P A, Bouhana K S, Gallegos A M, Agrawal A, Blanchard K S, Grimm S L, Jensen K L, Andrews L E, Wincott F E, Pitot P A, Tressler R J, Cushman C, Reynolds M A & Parry T J, Antitumor and antimetastatic activity of ribozyme targeting the m RNA of vascular endothelial growth factor receptor, Clin Cancer Res, 6 (2000) 2094-2103.
77. Gold L, RNA as the catalyst for drug screening, Nature Biotechnol, 20 (2002), 671-672.
78. Hartig, J S, Najafi-Shoushtari S H, Grüne I, Yan A, Ellington A D & Famulok M, Nature Biotechnol, 20 (2002) 717-722.
79. Seiwert S, Developing allosteric ribozymes for diagnostic, Nucleic acids discoveries-innovations in tools and targets (Mandalay Bay Resort and Casino, Las Vegas, NV) (April 30- May 2) 2003.
80. Wong- Staal F, The use of combinatorial ribozyme library for drug target discovery Nucleic acids discoveries-innovations in tools and targets (Mandalay Bay Resort and Casino, Las Vegas, NV) April 30- May 2 2003.
81. Rockett J C, Chip, chip array! Three chips for post genomic research, Drug Discovery Today, 7(8) (2002) 458-459.
82. Golub T R, Slonim D K, Tamayo P, Huard C, Gaasenbeek M, Mesirov J P, Coller H, Loh M L, Downing J R, Caligiuri M A, Bloomfield C D, & Lander E S, Molecular classification of cancer: class discovery and class prediction by gene expression profiling, Science, 286 (1999) 531-537.
83. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball C A, Causton H C, Wasteland T, Glenisson P, HolstegeF C P, Kim I F, Markowitz V, Matese J C, Parkinson H, Robinson A, Sarkans U, Schulze-Kremer S, Stewart J, Taylor R, Vilo J, & Vingron M, Minimum information about a microarray experiment (MIAME) - towards standards for microarray data. Nat Genet, 29 (2001) 365-371.
84. Foster W R & Huber R M, Current themes in microarray experimental design and analysis, Drug Discovery Today, 7(5) (2002) 290-292.
85. Clayton J, Chip based diagnostics for meningitis and food poisoning, Drug Discovery Today, 7(12) (2002) 637-638.
86. Doolittle R F, Biodiversity; microbial genomes multiply, Nature, 416 (2002) 697-700.
87. Coleman R A, Of mouse & man- what is the value of the mouse in predicting gene expression in human, Drug Discovery Today, 8(6) (2003) 233-235.
88. Marshall E, DNA arrays-Aftymetrix settles suit, fixes chips, Science, 291 (2001) 2535.
89. Pera M E et al., Isolation and characterization of multipotent clone of human embryonal carcinoma cells, Differentiation, 42 (1989) 10-23.
90. Shamblott M J, Axelman J, Wang S, Bugg E M, Littlefield J W, Donovan P J, Blumenthal P D, Huggins G R & Gearhart J D, Derivation of pluripotent stem cells from cultured human primordial germ stem cells, Proc Natl Acad Sci USA, 95 (1998) 13726-13731.
91. Paul G, Li J- Y & Brundin P, Stem cells; hype or hope? Drug Discovery Today, 7(5) (2002) 295-302.
92. Thayer A N, Great expectations, Chem Eng News, 10 (1998) 19-31.
93. Rader C, Antibodies libraries in drug and target discovery, Drug Discovery Today, 6(1) (2001) 36-43.
94. Walsh G, Biopharmaceutical benchmarks, Natl Biotechnol, 18 (2000) 831-833.
95. Jurcic J G et al., Monoclonal antibody therapy of cancer, Cancer Chemother Biol Response Modif, 17 (1997) 195-216.
96. FitzGerald K, In vitro display technologies- new tools for drug discovery, Drug Discovery Today, 5 (2000) 253-258.
97. Poul M A & Marks J D, Targeted gene delivery to mammalian cells by filamentasis bacteriophage, J Mol Biol, 288 (1999) 203-211.
98. Keyt B, Selection of oncology targets and development of human mAbs as Antitumor agents, IBC's Eighth Annu World Congr Agents Discovery Technology™ (Boston, M A) (August 10-15, 2003).
99. Fischkoft S, Taking the first phage- derived human antibody to the clinic, IBC's Eighth Annu World Congr Agents Discovery Technology™ (Boston, M A) (August 10-15, 2003).
100. Reff, M E, The discovery of Rityxan, IBC's Eighth Annu World Congr Agents Discovery Technology™ (Boston, M A) (August 10-15, 2003).
101. Hermann T & Patel D J, Adaptive recognition by nucleic acid aptamers, Science, 287 (2000) 820-825.
102. Brody E N & Gold L, Aptamers as therapeutic and diagnostic agents, J Biotechnol, 74 (2000) 5-13.
103. Burgstaller P, Girod A & Blind M, Aptamers as tool for target prioritization and lead identification, Drug Discovery Today, 7(24) (2002) 1221-1228.
104. Marshall K A & Ellington A D, In vitro selection of RNA-aptamers, Method Enzymol, 318 (2000) 193-214.
105. Cox J C & Ellington A D, Automated selection of anti protein aptamers, Bioorg Med Chem, 9 (2001) 2525-2531.
106. Kusser W, Chemically modified nucleic acids aptamers for in vitro solutions: evolving evolution, J Biotechnol, 74 (2000) 27-38.
107. Leva S, Lichte A, Burmeister J, Muhn P, Jahnke B, Fesser D, Erfurth J, Burgstaller P & Klussmann S, GnRH binding RNA and DNA spiegelmers. A novel approach toward GnRH Antagonism, Chem Biol, 9 (2002) 351-359.
108. Wlotzka B, Leva S, Eschgfäller B, Burmese J, Kleinjung F, Kaduk C, Muhn P, Hess-Stumpp H & Klussmann S, In vivo properties of an anti - GnRH spiegelemrs; an example of an oligonucleotide based therapeutic substanic class, Proc Natl Acad Sci USA, 99 (2002) 8898-8902.
109. Breaker R R, Engineered allosteric ribozymes as biosensor components, Curr Opin Biotechnol, 13 (2002) 31-39.
110. Jeong S & Yu J, RNA- aptamer as a specific modulator of Wnt signaling mediated carcinogenesis, Nucleic acids in drug discovery innovations in tools and target (Mandalay Bay Resort and Casino Las Vegas NV) April 30- May 2 2003.
111. Konopka K, Lee N S, Rossi J & Düzgüne N, Rev- binding aptamer and CMV promoter act as decoys to inhibit HIV replication, Gene, 255 (2000) 235-244.
112. Famulok M, Bringing picomolar protein detecrtion into proximity, Natl Biotechnol, (2002) 448-4449.
113. Wilkins M R, Pasquali C, Appel R D, Ou K, Golaz O, Sanchez J.-C, Yan J X, Gooley A A, Hughes G, Humphery-Smith I, Williams K L & Hochstrasser D F., From proteins to proteomics; large-scale protein identification by two dimensional electrophoresis and amino acid analysis, Biotechnol, 14 (1996) 61-65.
114. Tyres M & Mann M, From genomics to proteomics, Nature, 422 (6928) (2003) 193-197.
115. Hancock W & Faur P, The Challenges of shotgun sequencing in proteomics, American Genomic/ Proteomic Technol, 1 (2001) 54-58.
116. Aebersold R & Mann M, Mass- spectroscopy- based proteomics, Nature, 422 (6928) (2003) 198-207.
117. Phizicky E, Bastiaens P I H, Zhu H, Snyder M & Fields S, Protein analysis on a proteomics scale, Nature, 422 (6928) (2003) 208-215.
118. Sali A, Glaeser R, Earnest T & Baumeister W, From words to literature in structural proteomics, Nature, 422 (6928) (2003) 216-232.
119. Hanash S, Disease proteomics, Nature, 422 (6928) (2003) 226-232.
120. Boguski M S and McIntosh M W, Biomedical informatics for proteomics, Nature, 422 (6928) (2003) 233-237.
121. 0 resolution, Science, 289 (2000) 905-920.
122. Yee A, Chang X, Pineda-Lucena A, Wu B, Semesi A, Le B, Ramelot T, Lee G M, Bhattacharyya S, Gutierrez P, Denisov A, Lee C-H, Cort J R, Kozlov G, Liao J, Finak G, Chen L, Wishart D, Lee W, McIntosh L P, Gehring K, Kennedy M A, Edwards A M & Arrowsmith C H, An NMR- approach to structural proteomics. Proc Natl Acad Sci, USA, 99 (2002) 1825-1830.
123. Frank J, Single particle imaging of macromolecules by Cry-electron microscopy, Annu Rev Biophy Biomol Struct, 31 (2002) 303-319.
124. Ho Y, Gruhler A, Heilbut A, Bader G D, Moore L, Adams S-L, Millar A, Taylor P, Bennett K, Boutilier K, Yang L et al., Systematic identification of protein complexes in saccharomyces cerevisiac by mass spectroscopy, Nature, 415 (2002) 180-183.
125. Wouters F S, Verver P J & Bastiaens P I H, Imaging biochemistry inside cells, Trends Cell Boil, 11 (2001) 203-211.
126. Miras I. Schaeffer F, Beguin P & Alzari P M, Mapping by site directed mutagenesis of the region responsible for Cohesin-dockerin interaction on the surface of the seventh Cohesin domain of Clostridium thermocellum CipA, Biochemistry, 41 (2002) 2115-2119.
127. Lee Y-S & Mrksich M, Protein chips from concept of practice, Trends in Biotechnol (Suppl.) 20 (12) (2002) S 14-S 18.
128. Elia G, Silacci M, Scheurer S, Scheuermann J, & Neri D, Affinity- capture reagents for protein arrays, Trends in Biotechnol (Suppl.), 20 (12) (2002) S 19-S 22.
129. Singh Y, Pandey A, Dubey K K, Watal G & Misra K, Fluorescence Resonance Energy Transfer: A Diagnostic tool in oligonucleotide therapy, Curr Sci, 78(4) (2000) 487-492.
130. Shukla V, Mishra S, Watal G & Misra K, Design development and Synthesis of a novel labeled PNA monomer incorporated in DNA- hexamer to act as a hybridization probe by FRET, Org & Biomol Chem. (2003) (Communicated).
131. Petricoin E F, Ardekani A M, Hitt B A, Levine P J, Fusaro V A, Steinberg S M, Mills G B, Simone C & Fishman D A et al., Proteomic analysis at the bedside; early detection of cancer, Lancet, 359 (2002) 572-577.
132. Jones M B, Krutzsch H, Shu H, Zhao Y, Liotta L A, Kohn E C & Petricoin E F, Proteomics analysis and identification of new biomarkers and therapeutic targets for invasive ovarian, Proteomics, 2 (2002) 76-84.
133. Adam B L, Qu Y, Davis J W, Ward M D, Clements M A, Cazares L H, Semmes O J, Schellhammer P F, Yasui Y, Feng Z & Jr. G L Wright., Serum protein fingerprinting coupled with a pattern matching algorithm distinguishes prostate cancer from begin prostate hyperplasic & Healthy, men, Cancer Res, 62 (2002) 3609-3614.
134. Carter D, Douglass J F, Cornellison C D, Retter M W, Johnson J C, Bennington A A, Fleming T P, Reed S G, Houghton R L, Diamond D L & Vedvick T S, Purification and characterization of the mammaglobin lipophilin B complex, a promising diagnostic marker for breast cancer, Biochemistry, 28 (2002) 6714-6722.
135. Li J, Zhang Z, Rosenzweig J, Wang Y Y & Chan D W Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer, Clin Chem, 48 (2002) 1296-1304.
136. Bandara L R & Kennedy S, Toxicoproteomics - a new preclinical, Drug Discovery Today, 7(7) (2002) 411-418.
137. Fountoulakis M, Berndt P, Boclsterli U A, Crameri F, Winter M, Albertini S, Jones M B, Krutzsch H, Shu H, Zhao Y, Liotta L A, Kohn E C, Two dimensional data base of mouse liver proteins changes in hepatic protein levels following treatment with acetaminophen or its nontoxic egioisomer 3-occatamidophenol, Electrophesis, 21 (2000) 2148-2161.
138. Witzmann F A, Fultz C D, Grant R A, Wright L S, Kornguth S E & Siegel F L, Regional protein alternations in rat kidneys induced by lead exposure, Electrophoresis, 21 (1999) 976-984.
139. Arrell D K, Neverova I & Eyk J E V, Cardiovascular proteomics; evolution and potential, Circ Res, 88 (2001) 763-773.
140. Brichory F, Beer D, LeNaour F, Giordano T & Hanash S, Proteomic based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung, Cancer Res, 61 (2001) 7908-7912.
141. Halt S E, Is telomerase the cure all and end all?, Drug Discovery Today, 7(5) (2002) 88.
142. Mishra S, Tripathi S & Misra K, Synthesis of a novel anticancer prodrug designed to target telomerase sequence, Nucl Acids Res (suppl), No. 2 (2002) 277-278.
143. Heald R A, Modi C, Cookson J C, Hutchinson I, Laughton C A, Gowan S M, Kelland L R & Stevens M F G, Antitumor polycyclic acridies Synthetic and telomerase inhibitory activity of methylated pentacyclic acridinium salts, J Med Chem, 45 (2002) 590-597.
144. Southan C, A genomic perspective on human proteases as drug targets, Drug Discovery Today, 6(13) (2001) 681-688.
145. Cheng A, Uetani N, Simoncic P D, Chaubey V P, Lee-Loy A, McGlade C J, Kennedy B P, & Tremblay M L, Attenuation of leptin signal transduction obesity by protein tyrosine phosphatase 1β, Dev Cell, 2 (2002) 497-503.
146. Huijsduijnen R H, Bombrun A & Swinnen D, Selecting protein tyrosine phosphate as drug targets, Drug Discovery Today, 7(9) (2002) 1013-1019.
147. Hemmerich S, Carbohydrate sulfotransferases: novel therapeutic targets for inflammation, viral infection and cancer, Drug Discovery Today, 6(1) (2001) 27-35.